WO2020200284A1 - Procédé de préparation de composé tricyclique et son utilisation dans le domaine de la médecine - Google Patents

Procédé de préparation de composé tricyclique et son utilisation dans le domaine de la médecine Download PDF

Info

Publication number
WO2020200284A1
WO2020200284A1 PCT/CN2020/083004 CN2020083004W WO2020200284A1 WO 2020200284 A1 WO2020200284 A1 WO 2020200284A1 CN 2020083004 W CN2020083004 W CN 2020083004W WO 2020200284 A1 WO2020200284 A1 WO 2020200284A1
Authority
WO
WIPO (PCT)
Prior art keywords
dimethyl
triazol
compound
pyran
tetrahydro
Prior art date
Application number
PCT/CN2020/083004
Other languages
English (en)
Chinese (zh)
Inventor
张瑱
许忻
李云飞
武琦梅
张立明
王影
覃华
杨旭芹
李东升
刘磊
臧成旭
苏晶
秦成刚
段飞飞
王艺瑾
葛建
Original Assignee
上海华汇拓医药科技有限公司
浙江华海药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海华汇拓医药科技有限公司, 浙江华海药业股份有限公司 filed Critical 上海华汇拓医药科技有限公司
Priority to CN202080018606.1A priority Critical patent/CN113544129A/zh
Publication of WO2020200284A1 publication Critical patent/WO2020200284A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé tricyclique à petites molécules, son procédé de préparation, une composition pharmaceutique contenant ledit composé et son utilisation en médecine. Ledit composé est utilisé en tant qu'inhibiteur de protéine à bromodomaine 4 (BRD4), et peut être utilisé pour prévenir et/ou traiter des maladies associées à BRD4, telles que des tumeurs malignes.
PCT/CN2020/083004 2019-04-04 2020-04-02 Procédé de préparation de composé tricyclique et son utilisation dans le domaine de la médecine WO2020200284A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080018606.1A CN113544129A (zh) 2019-04-04 2020-04-02 三环类化合物制备方法及其在医药领域的应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910271014.X 2019-04-04
CN201910271014 2019-04-04

Publications (1)

Publication Number Publication Date
WO2020200284A1 true WO2020200284A1 (fr) 2020-10-08

Family

ID=72664643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/083004 WO2020200284A1 (fr) 2019-04-04 2020-04-02 Procédé de préparation de composé tricyclique et son utilisation dans le domaine de la médecine

Country Status (2)

Country Link
CN (1) CN113544129A (fr)
WO (1) WO2020200284A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530455A (ja) * 2018-06-25 2021-11-11 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドJacobio Pharmaceuticals Co., Ltd. 三環式化合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105324379A (zh) * 2013-05-09 2016-02-10 吉里德科学公司 作为溴结构域抑制剂的苯并咪唑衍生物
CN106029663A (zh) * 2013-12-24 2016-10-12 百时美施贵宝公司 作为抗癌剂的新颖三环化合物
WO2017124936A1 (fr) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 Dérivé de carboline servant comme inhibiteur de bromodomaines
CN107709322A (zh) * 2015-05-12 2018-02-16 百时美施贵宝公司 作为抗癌剂的三环化合物
WO2019080941A1 (fr) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. Nouveaux composés tricycliques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105324379A (zh) * 2013-05-09 2016-02-10 吉里德科学公司 作为溴结构域抑制剂的苯并咪唑衍生物
CN106029663A (zh) * 2013-12-24 2016-10-12 百时美施贵宝公司 作为抗癌剂的新颖三环化合物
CN107709322A (zh) * 2015-05-12 2018-02-16 百时美施贵宝公司 作为抗癌剂的三环化合物
WO2017124936A1 (fr) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 Dérivé de carboline servant comme inhibiteur de bromodomaines
WO2019080941A1 (fr) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. Nouveaux composés tricycliques

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530455A (ja) * 2018-06-25 2021-11-11 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドJacobio Pharmaceuticals Co., Ltd. 三環式化合物
US11466005B2 (en) 2018-06-25 2022-10-11 Jacobio Pharmaceuticals Co., Ltd. Tricyclic compounds
JP7168245B2 (ja) 2018-06-25 2022-11-09 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド 三環式化合物

Also Published As

Publication number Publication date
CN113544129A (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
CN111217797B (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN113999226B (zh) 作为kras抑制剂的杂环化合物的制备及其应用方法
CN109890797B (zh) 可用作抗癌剂的取代的碳核苷衍生物
TWI697486B (zh) 作為ｈｄａｃ抑制劑之３-芳基-４-醯胺基-雙環［４,５,０］異羥肟酸
JP6457623B2 (ja) ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用
KR20210121168A (ko) 복소환식 화합물인 벤조피리돈 및 그 사용
CN113286794A (zh) Kras突变蛋白抑制剂
WO2022135470A1 (fr) Préparation et procédé d'application d'un composé hétérocyclique utilisé en tant qu'inhibiteur de kras
WO2021143701A1 (fr) Composé hétérocyclique de pyrimidine-4(3h)-cétone, son procédé de préparation et son utilisation en médecine et en pharmacologie
JP6342069B2 (ja) アザビシクロ誘導体、その製造方法および医薬品における使用
WO2020011246A1 (fr) Composé contenant un cycle benzénique, son procédé de préparation et son utilisation
JP6760946B2 (ja) Ｈｓｐ９０阻害剤としてのレゾルシノール誘導体
CN113454086A (zh) 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物
CN114907341A (zh) 吡啶并嘧啶酮类衍生物及其制备方法和用途
CN111356695B (zh) 新的三环化合物
TW201348213A (zh) 喹唑啉二酮衍生物
WO2022194269A1 (fr) Nouvel agent de dégradation de l'egfr
CN114685531A (zh) 四并环化合物及其药物组合物和应用
WO2020192652A1 (fr) Procédé de préparation de composés amides et son utilisation dans le domaine médical
CN115536656A (zh) 作为hpk1抑制剂的杂环化合物
JP2023520396A (ja) アルファ１－アンチトリプシンのモジュレーター
WO2022199662A1 (fr) Composé polycyclique et son application
WO2020200284A1 (fr) Procédé de préparation de composé tricyclique et son utilisation dans le domaine de la médecine
CN110407854B (zh) 新的四环化合物
CN114057744A (zh) 制备kras g12c抑制剂咪唑并三嗪和吡咯并嘧啶衍生物的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20783316

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20783316

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20783316

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09/11/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20783316

Country of ref document: EP

Kind code of ref document: A1